Licensing Your Technology

The existence of relationships with outside entities that acquire emerging biomedical technologies by the Alfred Mann Foundation for Biomedical Engineering and AMIs expands the university’s network by providing very attractive opportunities for licensing, sale, or spin-out of AMI-enhanced biomedical technologies. During the licensing process, the Alfred Mann Foundation for Biomedical Engineering also assists with developing a presentation for the financial community that includes the expected metrics and highlights the features and benefits of the technology in an expected format.

Technology has or will be licensed or acquired by multinational lifescience companies such as Boston Scientific, Philips Medical, Medtronic, or to a company with a more focused product portfolio with a specific need for the technology to align with their distribution channels.

Some technologies will be transferred to individual start-up companies funded with follow on capital from other financial equity investment.

Established contacts with the entities that acquire technology ensure that technologies that emerge from Alfred Mann Institutes will receive a high level of attention, which will also support increased valuation at exit.

Universities that license biomedical technology at the basic research/discovery stage are likely to receive a low royalty rate, most often in the range of 1%, if and when a product is ultimately commercialized.

The likelihood of commercialization and rate of return can increase five-fold when manufacturing prototypes are completed by the university-based AMI. These rates of return can be further increased if licensing and transfer of technology to industry occurs closer to the point of FDA approval or certification.